Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multi-cohort, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With Clinical High-Risk Multiple Myeloma (KarMMa-2)

NCT03601078 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT03601078
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03601078 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multi-cohort, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With Clinical High-Risk Multiple Myeloma (KarMMa-2)
Lead sponsor
Celgene
Phase
Phase 2
Overall status
Completed
Start date
December 13, 2018
Completion date
January 15, 2026
Enrollment
312 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma